TRANSLATE

The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Special area involvement, disease severity, and treatments in a real-world psoriasis population

By Ella Dixon

Share:

Feb 21, 2024

Learning objective: After reading this article, learners will be able to cite a new clinical development in psoriasis.


Diagnosis of psoriasis is often based on clinical features, rather than histological examination. The use of tools such as body surface area (BSA), Physician’s Global Assessment, and the Psoriasis Area and Severity Index can help clinicians categorize the severity of psoriasis. However, these tools do not account for disease impact in special areas, such as the face, scalp, and genitals.

Here, we summarize a study by Horner et al.1 in Dermatology and Therapy, which described BSA distribution, special area involvement, and available treatments, to evaluate disease burden in a real-world setting.

Study design and patient population1

  • This retrospective study evaluated 5,120 patients with a BSA measured between 2014–2020.
  • Patients were aged ≥18 years, with at least one diagnosis of psoriasis within 90 days before and after the index date (the date of the first BSA value identified for the patient in the included data).
  • BSA categories at baseline:
    • 23.4% of patients had a BSA of <3%
    • 41.9% of patients had a BSA of 3–10%
    • 34.6% of patients had a BSA of >10%
  • Around half (49.3%) of patients were female, the majority were White (83.2%), and the most common comorbidities at baseline were hypertension (21.9%) and hyperlipidemia (17.8%).

Key findings1

  • In this real-world population, 77.3% had involvement in at least one special area (Figure 1A).
  • Areas of involvement are shown in Figure 1B, the most common special area involved was the scalp (43.3%).
  • The proportion of patients with involvement in two or more special areas was similar across the BSA categories.
  • Of the 4,470 patients evaluated for initial treatment, majority received biologics (31.1%) or topicals (41.5%) only. 78.9% of patients received any topicals alongside other treatments.
  • In patients with involvement of two or more special areas, the most common initial treatment was conventional synthetic anti-rheumatic drugs (54.1%), followed by topicals (48.3%), biologics (43.8%), and apremilast (43.5%).

Figure 1. A Several special areas are involved, and B prevalence of special areas by body location* 

*Adapted from Horner, et al.1 

Key learnings

  • Based on real-world data, most patients with special area involvement have a BSA of ≤10%.
  • In patients with two or more special areas involved, approximately half were treated with topicals.
  • These findings suggest that the International Psoriasis Council recommendations on use of systemics therapies are not reflected in the real-world, meaning patients who may benefit from systemic treatments are not being identified. Therefore, healthcare professionals should be aware of special areas and the associated recommendations when making prescribing decisions.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content